Ravi Paluri to Humans
This is a "connection" page, showing publications Ravi Paluri has written about Humans.
Connection Strength
0.428
-
Manne A, Kasi A, Esnakula AK, Paluri RK. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence. Int J Mol Sci. 2023 Apr 30; 24(9).
Score: 0.051
-
Paluri R, Laursen A, Gaeta J, Wang S, Surinach A, Cockrum P. Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States. Oncologist. 2022 Jun 08; 27(6):e518-e523.
Score: 0.048
-
Alkashash AM, Elsebaie MA, Bikhet MH, Morsi M, Paluri RK. Predictors of Survival among Early Onset Pancreatic Adenocarcinoma Patients A Tertiary Care Center Experience. Chirurgia (Bucur). 2021 Jan-Feb; 116(1):24-33.
Score: 0.043
-
Paluri RK, Li P, Anderson A, Nandagopal L, McArdle T, Young M, Robert F, Naik G, Saleh M. First-In-Human Phase 1 Clinical Trials - A Single-Center Experience In The Era Of Modern Oncotherapeutics. Sci Rep. 2020 05 13; 10(1):7935.
Score: 0.042
-
Paluri RK, Kasi A, Young C, Posey JA. Second-line treatment for metastatic pancreatic cancer. Clin Adv Hematol Oncol. 2020 Feb; 18(2):106-115.
Score: 0.041
-
Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2019 03; 83(3):551-559.
Score: 0.038
-
Regalla DKR, Williams GR, Paluri RK. Immune checkpoint inhibitors in the management of malignancies in transplant recipients. Postgrad Med J. 2018 Dec; 94(1118):704-708.
Score: 0.038
-
Paluri RK, Morgan CJ, Mooney DJ, Mgbemena O, Yang ES, Wei S, Kouba E, Naik G, El Mouallem NR, Poston T, Jones B, Nix J, Bolger GB, Deshazo M, Sonpavde G. Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the Bladder. Clin Genitourin Cancer. 2015 Oct; 13(5):469-75.
Score: 0.029
-
Paluri R, Nabell L, Borak S, Peker D. Unique presentation of blastic plasmacytoid dendritic cell neoplasm: a single-center experience and literature review. Hematol Oncol. 2015 Dec; 33(4):206-11.
Score: 0.027
-
Giri S, Mir N, Al-Obaidi M, Clark D, Kenzik KM, McDonald A, Young-Smith C, Paluri R, Nandagopal L, Gbolahan O, Nyrop KA, Muss HB, Pergolotti M, Bhatia S, Williams GR. Use of Single-Item Self-Rated Health Measure to Identify Frailty and Geriatric Assessment-Identified Impairments Among Older Adults with Cancer. Oncologist. 2022 Feb 03; 27(1):e45-e52.
Score: 0.012
-
Jamy O, Innis-Shelton R, Bal S, Paluri R, Salzman D, Di Stasi A, Costa L, Meredith R, Lamb L, Minagawa K, Mineishi S, Saad A. Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation. Am J Hematol. 2021 Oct 01; 96(10):E396-E398.
Score: 0.011
-
Giri S, Al-Obaidi M, Weaver A, Kenzik KM, McDonald A, Clark D, Young-Smith C, Paluri R, Nandagopal L, Gbolahan O, Pergolotti M, Bhatia S, Williams GR. Association Between Chronologic Age and Geriatric Assessment-Identified Impairments: Findings From the CARE Registry. J Natl Compr Canc Netw. 2021 Jun 11; 19(8):922-927.
Score: 0.011
-
Williams GR, Al-Obaidi M, Dai C, Mir N, Challa SA, Daniel M, Patel H, Barlow B, Young-Smith C, Gbolahan O, Paluri R, Bhatia S, Giri S. Association of malnutrition with geriatric assessment impairments and health-related quality of life among older adults with gastrointestinal malignancies. Cancer. 2020 12 01; 126(23):5147-5155.
Score: 0.011
-
Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 07 01; 17(7):855-883.
Score: 0.010
-
Jia X, Shanmugam C, Paluri RK, Jhala NC, Behring MP, Katkoori VR, Sugandha SP, Bae S, Samuel T, Manne U. Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget. 2017 Mar 21; 8(12):20198-20212.
Score: 0.008
-
Locke JA, Pond GR, Sonpavde G, Necchi A, Giannatempo P, Paluri RK, Niegisch G, Albers P, Buonerba C, Di Lorenzo G, Vaishampayan UN, North SA, Agarwal N, Hussain SA, Pal S, Eigl BJ. Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. Clin Genitourin Cancer. 2016 08; 14(4):331-40.
Score: 0.008